Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Sonrotoclax on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Sonrotoclax is a next-generation targeted tablet for two B-cell blood cancers: chronic lymphocytic leukaemia / small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL). It was discovered and developed by BeOne Medicines (formerly BeiGene). In China it is sold as 百悦达® (索托克拉片), and in the United States as BEQALZI™.
China's National Medical Products Administration (NMPA) gave it conditional approval on 30 December 2025, the first approval anywhere in the world, for adults with:
The US FDA followed in May 2026 with an accelerated approval for the MCL use. It is a prescription blood cancer medicine and should only be used under a haematologist.
Many B-cell cancers survive by making too much BCL2, a protein that stops damaged cells from switching on their own self-destruct programme. Sonrotoclax binds tightly to BCL2 and frees the signals that trigger that programme, so the cancer cells die. It has a short half-life and does not build up in the body.
It is a tablet taken once a day with food and water, swallowed whole. Treatment always starts with a step-by-step ramp-up to lower the risk of tumour lysis syndrome. For MCL, the US label uses a 4-week ramp-up (1 mg, 2 mg, 5 mg, 10 mg, 20 mg, 40 mg, 80 mg and 160 mg, each for a few days) and then 320 mg once daily, which was also the dose in the MCL trial. The Chinese label sets out the dosing for each approved use, and your haematologist will plan the exact schedule.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Tumour lysis syndrome (TLS): as the cancer cells die quickly, they can release enough salts and uric acid into the blood to upset its chemistry and strain the kidneys. In the MCL study, laboratory or clinical TLS occurred in 7% of 115 patients who followed the ramp-up. It can happen within hours of the first dose or a dose increase, so patients get fluids and a uric acid-lowering medicine beforehand, and blood tests are checked closely.
Overall: in the MCL study the most common side effects were pneumonia (16%), tiredness (16%), swelling (14%) and diarrhoea (14%). Serious side effects occurred in 37% of patients, and 8% stopped treatment because of them.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The tablets can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It has no CDSCO approval and is not sold in Indian pharmacies. It is approved in China (CLL/SLL and MCL) and in the United States (MCL only, accelerated approval); the European Medicines Agency has not approved it.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. For another import option after earlier treatment of CLL or MCL, see our page on Jaypirca.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. Because the first weeks use several low-dose steps, we plan the ramp-up supply and the later daily-dose supply separately with the treating haematologist. The tablets travel in their sealed original blister packs under temperature-controlled shipping and are stored as directed on the pack. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating hospital on a valid specialist's prescription.
Leading haematology units here treat lymphoma and CLL patients from across North India, and our New Delhi dispatch point keeps delivery quick.
The ramp-up supply can reach the hospital before day 1, so TLS checks and the first dose can be planned together.
Haematologists in Bangalore can request the medicine for a named patient, with the quote shared before anything is ordered.
A long-standing referral hub for lymphoma care in South India, familiar with named-patient import paperwork.
We line up each delivery with the dose steps in the haematologist's plan.
Patients in Kolkata and the eastern states can use the same documented route, with updates at every stage.
Families in Pune get a clear timeline from prescription check to delivery.
The treating doctor can send us the prescription and treatment history to begin the import.
Patients treated at hospitals in Vellore can have refills planned ahead so daily dosing is not interrupted.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to home or hospital.
We coordinate supply for patients treated at cancer hospitals across Uttar Pradesh.
Patients across Kerala can receive the tablets in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
